 |
PDBsum entry 2won
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
|
|
|
|
|
Enzyme class 1:
|
|
Chains A, B:
E.C.2.7.7.-
- ?????
|
|
|
|
|
|
|
Enzyme class 2:
|
|
Chains A, B:
E.C.2.7.7.49
- RNA-directed Dna polymerase.
|
|
|
|
|
|
|
Reaction:
|
|
DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) + diphosphate
|
|
|
|
|
|
DNA(n)
|
+
|
2'-deoxyribonucleoside 5'-triphosphate
|
=
|
DNA(n+1)
|
+
|
diphosphate
|
|
|
|
|
|
|
|
|
|
Enzyme class 3:
|
|
Chains A, B:
E.C.2.7.7.7
- DNA-directed Dna polymerase.
|
|
|
|
|
|
|
Reaction:
|
|
DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) + diphosphate
|
|
|
|
|
|
DNA(n)
|
+
|
2'-deoxyribonucleoside 5'-triphosphate
|
=
|
DNA(n+1)
|
+
|
diphosphate
|
|
|
|
|
|
|
|
|
|
Enzyme class 4:
|
|
Chains A, B:
E.C.3.1.-.-
|
|
|
|
|
|
|
Enzyme class 5:
|
|
Chains A, B:
E.C.3.1.13.2
- exoribonuclease H.
|
|
|
|
|
|
|
Reaction:
|
|
Exonucleolytic cleavage to 5'-phosphomonoester oligonucleotides in both 5'- to 3'- and 3'- to 5'-directions.
|
|
|
|
|
|
Enzyme class 6:
|
|
Chains A, B:
E.C.3.1.26.13
- retroviral ribonuclease H.
|
|
|
|
|
|
|
Enzyme class 7:
|
|
Chains A, B:
E.C.3.4.23.16
- HIV-1 retropepsin.
|
|
|
|
|
|
|
Reaction:
|
|
Specific for a P1 residue that is hydrophobic, and P1' variable, but often Pro.
|
|
|
|
|
|
|
|
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
|
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
| |
|
|
| |
|
|
Antimicrob Agents Chemother
54:4451-4463
(2010)
|
|
PubMed id:
|
|
|
|
|
|
| |
|
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
|
|
R.Corbau,
J.Mori,
C.Phillips,
L.Fishburn,
A.Martin,
C.Mowbray,
W.Panton,
C.Smith-Burchnell,
A.Thornberry,
H.Ringrose,
T.Knöchel,
S.Irving,
M.Westby,
A.Wood,
M.Perros.
|
|
|
|
|
| |
ABSTRACT
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
|
| |
PubMed id
|
|
Reference
|
|
|
|
|
|
J.J.Parienti,
and
G.Peytavin
(2011).
Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation.
|
| |
Expert Opin Drug Metab Toxicol,
7,
495-503.
|
|
|
|
|
|
|
L.H.Jones,
G.Allan,
R.Corbau,
D.S.Middleton,
C.E.Mowbray,
S.D.Newman,
C.Phillips,
R.Webster,
and
M.Westby
(2011).
Comparison of the non-nucleoside reverse transcriptase inhibitor lersivirine with its pyrazole and imidazole isomers.
|
| |
Chem Biol Drug Des,
77,
393-397.
|
|
|
|
|
|
|
P.Zhan,
and
X.Liu
(2011).
Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 - 2010).
|
| |
Expert Opin Ther Pat,
21,
717-796.
|
|
|
|
|
|
|
S.Ibe,
and
W.Sugiura
(2011).
Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.
|
| |
Future Microbiol,
6,
295-315.
|
|
|
|
|
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
|
|
|
Links
